Onxeo Logo

Onxeo

ALONX | PA

Overview

Corporate Details

ISIN(s):
FR0010095596 (+3 more)
LEI:
96950018AS30IUG0V528
Country:
France
Address:
49 BOULEVARD DU GENERAL MARTIAL VALIN, 75015 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Valerio Therapeutics, formerly known as Onxeo until June 2023, is a biotechnology company developing precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which utilizes two fully synthetic single-domain antibody (sdAb) libraries. This ultra-small sdAb platform is engineered for deep tissue penetration and highly precise therapeutic delivery, aiming to surpass the limitations of current treatments. Valerio's integrated approach combines predictive modeling for target identification, antibody engineering, and drug conjugate development. The company's strategy is to advance its therapeutic candidates to clinical proof-of-concept before forming strategic partnerships through co-development, out-licensing, and R&D collaborations to maximize the potential of its innovations.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Onxeo. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-05-06 17:06
Report Publication Announcement
Inside Information / Other news releases
English 245.0 KB
2025-05-06 17:06
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 247.1 KB
2025-03-19 15:27
Board/Management Information
Inside Information / Other news releases
English 146.6 KB
2025-03-19 12:30
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 192.3 KB
2025-03-19 12:30
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 257.6 KB
2025-03-03 17:35
Regulatory News Service
Informations privilégiées / Autres communiqués
French 274.6 KB
2025-03-03 17:35
Capital/Financing Update
Inside Information / Other news releases
English 207.6 KB
2024-11-15 08:00
Board/Management Information
Inside Information / Other news releases
English 132.0 KB
2024-11-15 08:00
Board/Management Information
Informations privilégiées / Autres communiqués
French 194.5 KB
2024-09-30 22:40
Interim Report
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
French 1.7 MB
2024-09-30 22:40
Interim Report
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
English 2.1 MB
2024-09-30 22:40
Earnings Release
Inside Information: News release on accounts, results
English 387.9 KB
2024-09-30 22:40
Interim Report
Inside Information: News release on accounts, results
French 373.1 KB
2024-09-30 07:00
M&A Activity
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 213.4 KB
2024-09-30 07:00
M&A Activity
Inside Information / Operations of the issuer (acquisitions, sales...)
English 276.8 KB

Automate Your Workflow. Get a real-time feed of all Onxeo filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Onxeo via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-09 N/A Other Other 17,857,143 5,000,000.04 EUR
2023-06-09 N/A Other Other 7,142,857 1,999,999.96 EUR

Peer Companies

Company Country Ticker View
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
AroCell AB Logo Sweden AROC
Arterra Bioscience Logo
Develops sustainable active ingredients from plant cell cultures for diverse industries.
Italy ABS
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP
Ascelia Pharma Logo
Developing novel drugs for rare cancer conditions, including an oral MRI contrast agent.
Sweden ACE
AVACTA GROUP PLC Logo
Developing targeted cancer therapies with a platform that delivers drugs directly to tumors.
United Kingdom AVCT
BenevolentAI Logo
AI-powered platform that analyzes biomedical data to accelerate drug discovery.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL inhibitors for cancer and severe respiratory infections.
Norway BGBIO
BioArctic Logo
Biopharma developing treatments & diagnostics for neurodegenerative diseases like Alzheimer's.
Sweden BIOA